How long does combined hormonal therapy suppress AMH levels in women with endometriomas? Results from an exploratory analysis of a clinical trial.
Lower Anti-Müllerian hormone (AMH) levels have been observed in women with ovarian endometriomas (OMA) undergoing combined hormonal contraceptive (CHC) therapy. However, the extent and timing of AMH recovery after CHC …
Association Between Sexual Orientation and the Impact, Diagnosis, and Treatment of Endometriosis.
Purpose: This study examined the association between sexual orientation and the impact, diagnosis, and treatment of endometriosis. Methods: An online survey was conducted in 2023 with 150 adults in the …
Urinary Urocortin as a Potential Non-Invasive Biomarker in Endometriosis: Exploratory Study with Histone H4.
Background and Objectives: Endometriosis, a complex and often underdiagnosed gynecological condition, frequently manifests with ovarian involvement, posing significant clinical challenges. Current diagnostic protocols primarily rely on invasive techniques, thus highlighting …
Identification of Adeno-Associate Virus (AAV) Serotype for Endometriosis Therapy and Effect of AAV-Mediated RNAi Delivery on Gene Expression and Cell Proliferation in In Vitro Endometrial Cell Culture.
Endometriosis is a chronic estrogen-dependent condition with limited treatment options, often requiring surgery and long-term hormonal therapy that may impair ovarian function. Despite advancements in gene therapy for other diseases, …
Impact of endometrioma management strategies on ovarian reserve over the follow-up period, a prospective longitudinal study.
The effects of current treatment options for endometrioma on ovarian reserve remain controversial. Recent advancements in surgical techniques may challenge the previously established evidence regarding the detrimental effects of surgery …